XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech’s position
Leveraging key advantages of AnaptysBio’s SHM-XEL platform, this approach rapidly generates high potency humanized therapeutic antibodies using minimal non-human sequence content. The newly issued US patent is assigned
The final rejection issued today finds the first claim of the reissue application, which is identical to the only claim in the ‘808 Patent, to be indefinite and
This patent provides Mersana broad coverage for its polymer-based Fleximer-ADC platform technology. The patent covers Fleximer-drug conjugates that can be linked to an antibody to create next-generation antibody
NiaCel is one of the first commercially available products to feature the ingredient NIAGEN from ChromaDex (CDXC), an innovative natural products company that provides proprietary ingredients and science-based
The PD-1 pathway (programmed cell death) is being actively pursued by most of the big pharmaceutical companies due to its critical role as a checkpoint in our immune
BioDiscovery’s Nexus Copy Number platform provides software offers simple yet powerful tools for copy number and sequence variation (CNV) analysis and visualization from microarrays and next generation sequencing
This model is used for drug stratification and identification of personalized drug treatments for cancer patients. The work began through a joint project between Alacris and the SAP(R)
The patent issued today expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke (EHS) was granted Orphan Drug designation by the Food and Drug
TD2 chief development officer Daniel Von Hoff said the Nuvilex team presents them with a new tool to employ against the symptoms and invasive properties of this very
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.